Imiquimod for anogenital warts in non-immunocompromised adults (Q24188125)

6

0 references

author name string

Carlos F Grillo-Ardila

1

0 references

Edith Angel-Müller

2

0 references

Luis C Salazar-Díaz

3

0 references

Hernando G Gaitán

4

0 references

Ariel I Ruiz-Parra

Cochrane Database of Systematic Reviews

5

0 references

publication date

1 November 2014

0 references

published in

0 references

cites work

Topical imiquimod 5% cream in external anogenital warts: a randomized, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010389.PUB2

Imiquimod 3.75% cream applied daily to treat anogenital warts: combined results from women in two randomized, placebo-controlled studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010389.PUB2

Treatment of genital warts with an immune-response modifier (imiquimod).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010389.PUB2

Self-administered topical 5% imiquimod cream for external anogenital warts. HPV Study Group. Human PapillomaVirus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010389.PUB2

Efficacy and safety of imiquimod versus podophyllotoxin in the treatment of anogenital warts

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010389.PUB2

Comparison of cryotherapy to imiquimod 5% in the treatment of anogenital warts

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010389.PUB2

A randomized, controlled, molecular study of condylomata acuminata clearance during treatment with imiquimod

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010389.PUB2

Imiquimod 5% cream in the treatment of anogenital warts in female patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010389.PUB2

Treatment of anogenital warts with imiquimod 5% cream followed by surgical excision of residual lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010389.PUB2

Systematic review of imiquimod for the treatment of genital warts: all that glitters is not gold

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010389.PUB2

Treatment of cutaneous warts: an evidence-based review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010389.PUB2

Treatment of external genital warts in men using 5% imiquimod cream applied three times a week, once daily, twice daily, or three times a day.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010389.PUB2

Imiquimod 5% cream is a safe and effective self-applied treatment for anogenital warts--results of an open-label, multicentre Phase IIIB trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010389.PUB2

Topical treatments for cutaneous warts

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010389.PUB2

Safety and efficacy of imiquimod 5% cream in the treatment of penile genital warts in uncircumcised men when applied three times weekly or once per day.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010389.PUB2

Optimal frequency of imiquimod (aldara) 5% cream for the treatment of external genital warts in immunocompetent adults: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010389.PUB2

Topical treatments for cutaneous warts

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010389.PUB2

A cost-effectiveness analysis of sinecatechins in the treatment of external genital warts

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010389.PUB2

Imiquimod 5% cream is an acceptable treatment option for external anogenital warts in uncircumcised males

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010389.PUB2

Critical appraisal of commonly used treatment for genital warts

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010389.PUB2

Green tea catechins for treatment of external genital warts

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010389.PUB2

Imiquimod for the treatment of genital warts: a quantitative systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010389.PUB2

New patient-applied therapy for anogenital warts is rated favourably by patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010389.PUB2

A study on the use of imiquimod for the treatment of genital molluscum contagiosum and genital warts in female patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010389.PUB2

Topical imiquimod 5% cream as an effective treatment for external genital and perianal warts in different patient populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010389.PUB2

Randomized, single-blind, placebo-controlled study of topical application of the immune response modulator resiquimod in healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010389.PUB2

Evaluation of imiquimod for the therapy of external genital and anal warts in comparison with destructive therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010389.PUB2

Management of female genital warts with an analog of imiquimod 2% in cream: a randomized, double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010389.PUB2

Treatment of external genital warts in men with imiquimod 2% in cream. A placebo-controlled, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010389.PUB2

Increased frequency of dosing of imiquimod 5% cream in the treatment of external genital warts in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010389.PUB2

The cost-effectiveness of patient-applied treatments for anogenital warts

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010389.PUB2

Meta-analysis of 5% imiquimod and 0.5% podophyllotoxin in the treatment of condylomata acuminata

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010389.PUB2

5-FU for genital warts in non-immunocompromised individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010389.PUB2

Interferon for anogenital warts in non-immunocompromised adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010389.PUB2

Imiquimod and resiquimod as novel immunomodulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010389.PUB2

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010389.PUB2

Human papillomavirus update with a particular focus on cervical disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010389.PUB2

A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010389.PUB2

Natural history of cervicovaginal papillomavirus infection in young women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010389.PUB2

Imiquimod 5% cream: a topical immune response modifier

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010389.PUB2

The management of anogenital [correction of anal] warts

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010389.PUB2

Modern management of external genital warts

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010389.PUB2

Review Article Imiquimod applied topically: a novel immune response modifier and new class of drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010389.PUB2

The antitumoral mode of action of imiquimod and other imidazoquinolines

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010389.PUB2

The use of sinecatechins (polyphenon E) ointment for treatment of external genital warts

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010389.PUB2

European course on HPV associated pathology: guidelines for primary care physicians for the diagnosis and management of anogenital warts

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010389.PUB2

Topical imiquimod: a review of its use in the management of anogenital warts, actinic keratoses, basal cell carcinoma and other skin lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010389.PUB2

Sexually Transmitted Diseases Among American Youth: Incidence and Prevalence Estimates, 2000

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010389.PUB2

External genital warts: diagnosis, treatment, and prevention.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010389.PUB2

Imiquimod for anogenital warts in non-immunocompromised adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010389.PUB2

Immunostimulation to reduce recurrence after surgery for anal condyloma acuminata: a prospective randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010389.PUB2

Enhancement of the innate and cellular immune response in patients with genital warts treated with topical imiquimod cream 5%

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010389.PUB2

7 January 2021

Imiquimod applied topically: a novel immune response modifier and new class of drug

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010389.PUB2

7 January 2021

Imiquimod, a patient-applied immune-response modifier for treatment of external genital warts.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010389.PUB2

7 January 2021

An open-label phase II pilot study investigating the optimal duration of imiquimod 5% cream for the treatment of external genital warts in women

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010389.PUB2

7 January 2021

Topical treatment of anogenital human papillomavirus infection in male patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010389.PUB2

7 January 2021

10.1002/14651858.CD010389.PUB2

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

Consolidated OpenCitations Corpus – April 2017

PubMed publication ID

25362229

1 reference

Consolidated OpenCitations Corpus – April 2017